⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13113895 | 0.81 | — | — | |
| SCHEMBL5217978 | 0.80 | — | — | |
| SCHEMBL5217970 | 0.80 | — | — | |
| SCHEMBL104854 | 0.71 | — | — | |
| SCHEMBL29452696 | 0.67 | — | — | |
| SCHEMBL7562766 | 0.62 | — | — | |
| Methane SCHEMBL27532449 | 0.61 | — | — | |
| SCHEMBL25407819 | 0.55 | — | — | |
| SCHEMBL17688346 | 0.55 | — | — | |
| SCHEMBL24013 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4670 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | claimed |
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2024-06-13 | — | — | US | claimed |
| CN-117157299-B | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| EP-4368625-A1 | SHP2 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-05-15 | — | — | EP | claimed |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-02 | — | — | US | claimed |
| CN-117916242-A | SHP2 inhibitors and uses thereof | 治纳辅医药科技有限公司 | 2024-04-19 | — | — | CN | claimed |
| US-11945798-B2 | Substituted aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2024-04-02 | — | — | US | claimed |
| US-20230399314-A1 | CD73 INHIBITOR AND USE THEREOF | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-12-14 | — | — | US | claimed |
| CN-117157299-A | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2023-12-01 | — | — | CN | claimed |
| EP-4103566-B1 | FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS | ASTRAZENECA AB (SE) | 2023-10-04 | — | — | EP | claimed |
| EP-0882042-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | AstraZeneca UK Limited (GB) | 1998-12-09 | — | — | EP | claimed |
| WO-1998023587-A1 | 5-CYCLO INDOLE COMPOUNDS AS 5-HT1D RECEPTOR LIGANDS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1998-06-04 | — | — | WO | claimed |
| WO-1997043280-A1 | 3-PHENYL-FURAN-(5H)-2-ONE AND DIHYDROFURAN-2-ONE DERIVATIVES AS ANTIBACTERIAL AGENTS | ZENECA LIMITED (GB) | 1997-11-20 | — | — | WO | claimed |
| WO-1997030995-A1 | ANTIBIOTIC OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-28 | — | — | WO | claimed |
| EP-0282456-A2 | Mylbemycin derivatives to combat parasites on animals | CIBA-GEIGY AG (CH) | 1988-09-14 | — | — | EP | claimed |
| US-4735937-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-04-05 | — | — | US | claimed |
| EP-0253767-A1 | Parasiticide and insecticide | CIBA-GEIGY AG (CH) | 1988-01-20 | — | — | EP | claimed |
| EP-0236939-A1 | Derivatives of 5-acyloxy-13-beta-alkyl milbemicyne against parasites in animals and plants | CIBA-GEIGY AG (CH) | 1987-09-16 | — | — | EP | claimed |
| EP-0035046-B1 | NOVEL TETRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND ANTI-ULCER COMPOSITION CONTAINING THE SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1985-10-02 | — | — | EP | claimed |
| US-4430498-A | 8-Oxo-5-thia-1-azabicyclo(4,2,0)oct-2-ene compounds | CIBA-GEIGY CORPORATION (US) | 1984-02-07 | — | — | US | claimed |